GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Samsung Biologics Renews Manufacturing Deal to Expand Production of TG Therapeutics’ Cancer Drug

by Tyler Chen
Share To

For the fourth time since February 2018, Korea’s Samsung Biologics renewed a large-scale contract manufacturing deal with TG Therapeutics to produce the latter’s blood cancer drug ublituximab (TG-1101). The expanded collaboration saw the deal leap from $21.7 million (24.1 billion won) to $48.5 million (54.1 billion won) in value.

“We are very glad to be able to flexibly accommodate our client’s expanded needs through our facilities,” said John Rim, CEO of Samsung Biologics. “By supporting TG Therapeutics in this partnership, we are contributing to bringing needed treatments to patients around the world and getting a step closer to our vision of bringing about a better life for humanity.”

Combo Therapy Against Chronic Lymphocytic Leukemia

Ublituximab is an investigational monoclonal antibody that can target a specific epitope on CD20-expressing B cells. It elicits immunological reactions, including antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), and causes cell destruction.

Ublituximab is in development for treating patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). The drug registered a strong showing in the Phase 3 UNITY-CLL trial where it was evaluated along with UKONIQTM (umbralisib), TG Therapeutics’ oral once-daily inhibitor of PI3K-delta and CK1-epsilon. Based on the positive results, TG Therapeutics submitted a Biologics License Application to the FDA for the combination therapy.

“This is an important next step in our long-standing relationship with Samsung,” said Michael S. Weiss, Executive Chairman and CEO of TG Therapeutics.

“With the recent positive ULTIMATE I and II MS Phase 3 studies, we re-evaluated our supply needs and were very pleased we were able to secure the long-term capacity we believe we will need to meet the potential global demand for ublituximab.”

Besides CLL, ublituximab also impressed in two other Phase 3 trials in patients with relapsing forms of multiple sclerosis (RMS). TG Therapeutics is currently preparing a BLA for this indication as well.

Related Article: Korea Made Humira Biosimilar Begins Sales in Australia, Marks its Presence in Third Overseas Market

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top